# Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

> **NCT00667862** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT00667862
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-18
- **Primary completion:** 2010-11-05
- **Final completion:** 2010-11-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667862, "Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00667862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*